Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

162.70
-1.8200-1.11%
Post-market: 161.65-1.0452-0.64%19:43 EDT
Volume:2.88M
Turnover:468.05M
Market Cap:252.35B
PE:24.36
High:163.54
Open:163.52
Low:161.18
Close:164.52
52wk High:212.71
52wk Low:145.79
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.99
T/O Rate:0.19%
Dividend:3.16
Dividend Rate:1.94%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.02%
PB:5.02
PE(LYR):24.88

Loading ...

AstraZeneca PLC Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 29

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

AstraZeneca Targets Pediatric Asthma Gains With New Glycopyrronium Trial

TIPRANKS
·
Aug 28

AstraZeneca Advances Off‑the‑Shelf CAR‑T Program in Tough‑to‑Treat Multiple Myeloma

TIPRANKS
·
Aug 28

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

TIPRANKS
·
Aug 27

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

TIPRANKS
·
Aug 27

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live
·
Aug 27

AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals

Dow Jones
·
Aug 27

AstraZeneca Slides Wednesday, Underperforms Market

Dow Jones
·
Aug 27

AstraZeneca Deepens Its Type 2 Diabetes Pipeline With New Global Patient Mapping Study

TIPRANKS
·
Aug 26

AstraZeneca Climbs Tuesday, Outperforms Market

Dow Jones
·
Aug 26

AstraZeneca (AZN) Receives a Sell from Deutsche Bank

TIPRANKS
·
Aug 25

Astrazeneca Prices $2.97 Billion Eurobond Offering

MT Newswires Live
·
Aug 25

AstraZeneca’s AZD4144 Interaction Study Adds Quiet Support to AZN’s Pipeline Story

TIPRANKS
·
Aug 25

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 25

AstraZeneca Rallies Friday, Outperforms Market

Dow Jones
·
Aug 22

AstraZeneca’s SELENE 3 Trial Targets Extra Weight-Loss Upside for AZN Investors

TIPRANKS
·
Aug 21

AstraZeneca PLC Stock Rises Thursday, Outperforms Market

Dow Jones
·
Aug 21

Dizhe Pharma Surpasses 500 Million Yuan in First-Half Revenue, Seals Global Exclusive Licensing Pact with AstraZeneca for Sunvozertinib

Deep News
·
Aug 20

Third Indication Approved in China for AstraZeneca's Ultomiris

Stock News
·
Aug 20